Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chad Moretz

Showing results (11-20 of 43) with videos related to

Pageof 5
Sort By:
Current Medical Research and Opinion|July 9, 2015
Historical cohort analysis of treatment patterns for patients with type 2 diabetes initiating metformin monotherapyLeslie Hazel-Fernandez, Yihua Xu, Chad Moretz, et al.
International Journal of Chronic Obstructive Pulmonary Disease|December 15, 2015
COPD exacerbation frequency and its association with health care resource utilization and costsAmol D Dhamane, Chad Moretz, Yunping Zhou, et al.
International Journal of Chronic Obstructive Pulmonary Disease|January 6, 2017
Association between adherence to medications for COPD and medications for other chronic conditions in COPD patientsAmol D Dhamane, Phil Schwab, Sari Hopson, et al.
International Journal of Chronic Obstructive Pulmonary Disease|September 28, 2020
Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating Patients with COPD Receiving Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance TherapyChad Moretz, Ashley L Cole, George Mu, et al.
International Journal of Chronic Obstructive Pulmonary Disease|March 7, 2017
Impact of comorbid conditions in COPD patients on health care resource utilization and costs in a predominantly Medicare populationPhil Schwab, Amol D Dhamane, Sari D Hopson, et al.
Journal of the American Pharmacists Association : Japha|October 15, 2022
Implementing comprehensive pharmacogenomics in a community hospital-associated primary care settingJennifer A Wick, Tara Schmidlen, Kendra Grande, et al.
Journal of Comparative Effectiveness Research|May 30, 2018
Factors influencing dabigatran or warfarin medication persistence in patients with nonvalvular atrial fibrillationSrinivas Annavarapu, Pranav K Gandhi, Yong Li, et al.
Journal of Cardiopulmonary Rehabilitation|August 24, 2006
Validity and reliability of the North Carolina 6-minute cycle testDavid E Verrill, Lauren Fox, J Brian Moore, et al.
Journal of Personalized Medicine|December 23, 2022
Validation of Pharmacogenomic Interaction Probability (PIP) Scores in Predicting Drug-Gene, Drug-Drug-Gene, and Drug-Gene-Gene Interaction Risks in a Large Patient PopulationKristine Ashcraft, Kendra Grande, Sara L Bristow, et al.
BMC Pulmonary Medicine|August 1, 2021
Time-to-first exacerbation, adherence, and medical costs among US patients receiving umeclidinium/vilanterol or tiotropium as initial maintenance therapy for chronic obstructive pulmonary disease: a retrospective cohort studyDavid Slade, Riju Ray, Chad Moretz, et al.
Pageof 5

Showing results (11-20 of 43) with videos related to

Sort By:
Pageof 5
Current Medical Research and Opinion|July 9, 2015
Historical cohort analysis of treatment patterns for patients with type 2 diabetes initiating metformin monotherapyLeslie Hazel-Fernandez, Yihua Xu, Chad Moretz, et al.
International Journal of Chronic Obstructive Pulmonary Disease|December 15, 2015
COPD exacerbation frequency and its association with health care resource utilization and costsAmol D Dhamane, Chad Moretz, Yunping Zhou, et al.
International Journal of Chronic Obstructive Pulmonary Disease|January 6, 2017
Association between adherence to medications for COPD and medications for other chronic conditions in COPD patientsAmol D Dhamane, Phil Schwab, Sari Hopson, et al.
International Journal of Chronic Obstructive Pulmonary Disease|September 28, 2020
Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating Patients with COPD Receiving Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance TherapyChad Moretz, Ashley L Cole, George Mu, et al.
International Journal of Chronic Obstructive Pulmonary Disease|March 7, 2017
Impact of comorbid conditions in COPD patients on health care resource utilization and costs in a predominantly Medicare populationPhil Schwab, Amol D Dhamane, Sari D Hopson, et al.
Journal of the American Pharmacists Association : Japha|October 15, 2022
Implementing comprehensive pharmacogenomics in a community hospital-associated primary care settingJennifer A Wick, Tara Schmidlen, Kendra Grande, et al.
Journal of Comparative Effectiveness Research|May 30, 2018
Factors influencing dabigatran or warfarin medication persistence in patients with nonvalvular atrial fibrillationSrinivas Annavarapu, Pranav K Gandhi, Yong Li, et al.
Journal of Cardiopulmonary Rehabilitation|August 24, 2006
Validity and reliability of the North Carolina 6-minute cycle testDavid E Verrill, Lauren Fox, J Brian Moore, et al.
Journal of Personalized Medicine|December 23, 2022
Validation of Pharmacogenomic Interaction Probability (PIP) Scores in Predicting Drug-Gene, Drug-Drug-Gene, and Drug-Gene-Gene Interaction Risks in a Large Patient PopulationKristine Ashcraft, Kendra Grande, Sara L Bristow, et al.
BMC Pulmonary Medicine|August 1, 2021
Time-to-first exacerbation, adherence, and medical costs among US patients receiving umeclidinium/vilanterol or tiotropium as initial maintenance therapy for chronic obstructive pulmonary disease: a retrospective cohort studyDavid Slade, Riju Ray, Chad Moretz, et al.
Pageof 5